company-header-background
Pre-Clinical
Only a small percentage of the thousands of compounds tested during the discovery phase possess the desired activity and are now designated as “hits”.
Pre-clinical Formulation Approaches

A handful of the most promising hits are chosen for modification to improve target specificity, potency, chemical and metabolic stability, water solubility, and other pharmacological parameters

Polymeric Nanoparticle

Before anything is given to humans, safety and efficacy tests are conducted using computerized models, cells, and animals. The NanoAssemblr® Blaze was developed to bridge the gap between nanoparticle discovery and clinical development.

 

The development of an overall formulation strategy to support in vivo studies should be considered carefully as it can reduce cycle time and resources. This strategy must be comprehensive, encompassing early studies designed to identify and validate drug targets, to long-term toxicology studies and ultimately, to support clinical studies in humans.

 


 

 

 


Pre-Clinical Phase Solutions
NanoAssemblr Benchtop
During the Pre-Clinical stage, the NanoAssemblr® Benchtop manufactures 1 – 15 mL of nanomedicine per run for continued optimization, preliminary stability studies and in vivo testing in small models.
NanoAssemblr Blaze

 

The dynamic volume range allows researchers to use the Blaze for in vivo studies in larger models, preclinical toxicology testing, early Chemistry, Manufacturing and Controls (CMC) studies and downstream process development.


Formulation Scientists in a Lab

 

Our services will provide you with a formulation and a technology transfer into a production facility that you can be confident will be suitable for clinical scale-up. PNI offers highly qualified scientist through our Formulation Solutions Team. 


Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to Liposomes

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Romano, D.T. O'Hagan, U. D'Oro, ...

Read More 阅读更多

Publication - Abstract

December 31, 2019

Vaccines

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerated in Healthy Adults ...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith, Ö. Almarsson, H.S. Pujar, M....

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, et al.

Read More 阅读更多

Publication - Summary

May 17, 2019

Science Immunology

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

N. Kose, J.M. Fox, G. Sapparapu, et al.

Read More 阅读更多

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More 阅读更多
Resource Center 资源中心
MENU
菜单
X
X